Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
Hasdai D, Holmes DR Jr, Criger DA, Topol EJ, Califf RM, Wilcox RG, Paolasso E, Simoons M, Deckers J, Harrington RA. Hasdai D, et al. Among authors: topol ej. Am Heart J. 2000 Mar;139(3):454-60. doi: 10.1016/s0002-8703(00)90089-9. Am Heart J. 2000. PMID: 10689260 Clinical Trial.
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ. Mukherjee D, et al. Among authors: topol ej. Am Heart J. 2002 Dec;144(6):995-1002. doi: 10.1067/mhj.2002.126118. Am Heart J. 2002. PMID: 12486423 Clinical Trial.
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman EM, Granger CB, Van de Werf F, Simoons ML, O'connor CM, Holmes DR Jr. Hasdai D, et al. Among authors: topol ej. Am Heart J. 2003 Jan;145(1):73-9. doi: 10.1067/mhj.2003.53. Am Heart J. 2003. PMID: 12514657
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Lincoff AM, et al. Among authors: topol ej. J Am Coll Cardiol. 1997 Jul;30(1):149-56. doi: 10.1016/s0735-1097(97)00110-1. J Am Coll Cardiol. 1997. PMID: 9207636 Free article. Clinical Trial.
Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ. Mak KH, et al. Among authors: topol ej. Am J Cardiol. 1997 Oct 15;80(8):985-8. doi: 10.1016/s0002-9149(97)00589-4. Am J Cardiol. 1997. PMID: 9352964 Clinical Trial.
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Alexander JH, et al. Among authors: topol ej. Am J Cardiol. 1999 Apr 15;83(8):1147-51. doi: 10.1016/s0002-9149(99)00049-1. Am J Cardiol. 1999. PMID: 10215274 Clinical Trial.
1,207 results